KR900009064A - 활성 성분으로서 피소스티그민으로 구성된 경피 치료계 및 그것의 제조방법 - Google Patents

활성 성분으로서 피소스티그민으로 구성된 경피 치료계 및 그것의 제조방법 Download PDF

Info

Publication number
KR900009064A
KR900009064A KR1019890019755A KR890019755A KR900009064A KR 900009064 A KR900009064 A KR 900009064A KR 1019890019755 A KR1019890019755 A KR 1019890019755A KR 890019755 A KR890019755 A KR 890019755A KR 900009064 A KR900009064 A KR 900009064A
Authority
KR
South Korea
Prior art keywords
therapeutic system
transdermal therapeutic
physostigmine
weight
polymer
Prior art date
Application number
KR1019890019755A
Other languages
English (en)
Other versions
KR950015057B1 (ko
Inventor
힐레 토마스
호프만 한스-라이너
후버 한스-요아힘
악셀크노흐
슈나이더 게라르트
슈타니스라우스 프리츠
Original Assignee
원본미기재
엘테에스 로만 테라파 시스테메 게엠베하 운트 콤파니 카게
클링게 파르마 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 엘테에스 로만 테라파 시스테메 게엠베하 운트 콤파니 카게, 클링게 파르마 게엠베하 filed Critical 원본미기재
Publication of KR900009064A publication Critical patent/KR900009064A/ko
Application granted granted Critical
Publication of KR950015057B1 publication Critical patent/KR950015057B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

내용 없음.

Description

활성 성분으로서 피소스티그민으로 구성된 경피 치료계 및 그것의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 매트릭스(1)에 도포된 부직포(2)를 나타낸다.
제2도는 분리후 매트릭스(1)과 밀폐커버(3)위에 배치된 활성제 수용체(2)의 정면도를 나타낸다.
제3도는 분리후 매트릭스(1)과 밀폐커버(3)위에 배치된 활성기제 수용체(2)의 측면도를 나타낸다.

Claims (16)

  1. 활성물질, 압감 접찹 수요층, 및 임의의 제거성 보호층에 불투과성인 커버층을 경유하여 피부에 피소스티그민을 투여하는 경피 치료계에 있어서, 수용층의 스티렌과 1,3-디엔을 기초로한 블록 공중합체, 폴리이소부틸렌, 아크릴레이트 및/또는 메타아크릴레이트 및 수소화 콜로포늄의 에스테르를 기초로한 중합체로 구성된 군으로부터 선택된 10-90중량%의 중합물질, 탄화수소 및/또는 에스테르를 기초로한 0-30중량%의 연질제로 구성되며, 제조직후 융착된 활성물질이 0.1-70중량%의 피소스티그민중에 15-85중량%로 구성되는 것을 특징으로 하는 경피 치료계.
  2. 제1항에 있어서, 중합물질이 Z-에틸헥실 아크릴레이트, 비닐아세테이트, 아크릴산 및 그것의 티탄 킬레이트의 자기 가교결합 아크릴 레이트 공중합체로 구성되는 것을 특징으로 하는 경피 치료계.
  3. 제1항에 있어서, 중합물질이 Z-에틸헥실 아크릴레이트, 비닐 아세테이트 및 아크릴산의 비자기 가교결합 아크릴레이트 공중합체로 구성되는 것을 특징으로 하는 경피 치료계.
  4. 제1항에 있어서, 중합물질이 메타아크릴레이트를 기초로한 중합체, 디메틸 아미노에틸 메타아크릴레이트 및 중성 메타 아크릴산 에스테르를 기초로한 공중합체로 구성되는 것을 특징으로 하는 경피 치료계.
  5. 제1항에 있어서, 중합물질이 수소화 콜로포늄의 에스테르 또는 그것의 메틸 에스테르로 구성되는 것을 특징으로 하는 경피 치료계.
  6. 제1항에 있어서, 중합물질이 수소화 콜로포늄의 에스테르 또는 그것의 글리콜 에스테르로 구성되는 것을 특징으로 하는 경피 치료계.
  7. 제1항에 있어서, 수용층이 디옥틸시클로 헥산 연질제로서 구성되는 것을 특징으로 하는 경피 치료계.
  8. 제1항에 있어서, 수용층이다.-n-부틸 아디페이트 연질제로 구성되는 것을 특징으로 하는 경피 치료계.
  9. 제1항에 있어서, 수용층이 트리글리세리드 연질제로 구성되는 것을 특징으로 하는 경피 치료계.
  10. 제1항에 있어서, 수용층이 이소프로필미스테이트 연질제로 구성되는 것을 특징으로 하는 경피 치료계.
  11. 제1항에 있어서, 활성 융착 물질내에서 피소스티그민 용액의 용매가 최소한 하나의 산기를 가진 화합물인 것을 특징으로 하는 경피 치료계.
  12. 제1항에 있어서, 적어도 하나의 산기로 구성된 화합물이 카르복실산인 것을 특징으로 하는 경피 치료계.
  13. 제12항에 있어서, 카르복실산이 올레인 산 또는 운데센 산으로 구성되는 것을 특징으로 하는 경피 치료계.
  14. 제12항에 있어서, 카르복실산이 운데칸 산의 혼합물로 구성되는 것을 특징으로 하는 경피 치료계.
  15. 제12항에 있어서, 카르복실산이 베르사틴 산으로 구성되는 것을 특징으로 하는 경피 치료계.
  16. 제거성 보호층이 선택적으로 제공된 예비 제조된 자기 접착매트릭스 위에 위치딘 직물에 피소스티그민 또는 그것의 약학적 허용염을 용액내에서 첨가한 다음, 매트릭스와 활성 융착 물질에 커버층이 제공되는 것을 특징으로 하는 제1항의 경피 치료계의 제조방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890019755A 1988-12-22 1989-12-22 활성 성분으로서 피소스티그민을 포함하는 경피 치료계 및 이의 제조방법 KR950015057B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3843238A DE3843238C1 (ko) 1988-12-22 1988-12-22
DEP3843238.2 1988-12-22

Publications (2)

Publication Number Publication Date
KR900009064A true KR900009064A (ko) 1990-07-02
KR950015057B1 KR950015057B1 (ko) 1995-12-21

Family

ID=6369854

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890019755A KR950015057B1 (ko) 1988-12-22 1989-12-22 활성 성분으로서 피소스티그민을 포함하는 경피 치료계 및 이의 제조방법

Country Status (29)

Country Link
US (1) US5391375A (ko)
EP (1) EP0377147B1 (ko)
JP (1) JPH0784380B2 (ko)
KR (1) KR950015057B1 (ko)
CN (1) CN1044226A (ko)
AT (1) ATE105489T1 (ko)
AU (1) AU613814B2 (ko)
CA (1) CA2006398C (ko)
CS (1) CS277067B6 (ko)
DD (1) DD290582A5 (ko)
DE (2) DE3843238C1 (ko)
DK (1) DK651189A (ko)
ES (1) ES2057080T3 (ko)
FI (1) FI95774C (ko)
GE (1) GEP19980993B (ko)
HU (1) HU206041B (ko)
IE (1) IE64834B1 (ko)
IL (1) IL92679A0 (ko)
LT (1) LT3705B (ko)
LV (1) LV10383B (ko)
MY (1) MY105073A (ko)
NO (1) NO180107C (ko)
NZ (1) NZ231908A (ko)
PH (1) PH25852A (ko)
PL (1) PL160971B1 (ko)
PT (1) PT92651B (ko)
RU (1) RU2052997C1 (ko)
YU (1) YU47076B (ko)
ZA (1) ZA899882B (ko)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3843239C1 (ko) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
US5241925A (en) * 1988-12-27 1993-09-07 Dermamed Apparatus and techniques for administering veterinary medicaments
US5332577A (en) * 1988-12-27 1994-07-26 Dermamed Transdermal administration to humans and animals
US5252334A (en) * 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
US5324521A (en) * 1989-12-18 1994-06-28 Dermamed Systems for transdermal administration of medicaments
DE4020144A1 (de) * 1990-06-25 1992-01-09 Lohmann Therapie Syst Lts Pflaster mit hohem gehalt an weichmachenden inhaltsstoffen
GB9118028D0 (en) * 1991-08-21 1991-10-09 Secr Defence Brit Improved transdrmal formulations
US5619351A (en) * 1992-07-13 1997-04-08 Seiko Epson Corporation Surface-type illumination device and liquid crystal display
DE4238223C1 (de) * 1992-11-12 1994-05-26 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Verabreichung von Physostigmin an die Haut und Verfahren zu dessen Herstellung
US5762952A (en) * 1993-04-27 1998-06-09 Hercon Laboratories Corporation Transdermal delivery of active drugs
DE4332094C2 (de) * 1993-09-22 1995-09-07 Lohmann Therapie Syst Lts Lösemittelfrei herstellbares Wirkstoffpflaster und Verfahren zu seiner Herstellung
DE4342174C1 (de) * 1993-12-10 1995-05-11 Lohmann Therapie Syst Lts Transdermales therapeutisches System sowie ein Verfahren zur Herstellung eines transdermalen therapeutischen Systems zur kombinierten transdermalen Anwendung von Physostigmin und Scopolamin für die Prophylaxe und zur Vorbehandlung einer Vergiftung durch hochtoxische phosphororganische Nervengifte, insbesondere Soman und seine Verwendung
DE4429791C2 (de) * 1994-08-23 1997-04-24 Lohmann Therapie Syst Lts Medizinischer Haftkleber auf Basis von Polyacrylaten und dessen Verwendung
DE60138019D1 (de) * 2000-05-01 2009-04-30 Accera Inc Verwendung von triglyceriden mit mittellangen ketten zur behandlung und vorbeugung der alzheimerschen erkrankung
US6440465B1 (en) * 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US20070179197A1 (en) * 2000-05-01 2007-08-02 Accera, Inc. Compositions and methods for improving or preserving brain function
US20060189545A1 (en) * 2003-03-06 2006-08-24 Henderson Samuel T Novel chemical entities and methods for their use in treatment of metabolic disorders
US20060252775A1 (en) * 2005-05-03 2006-11-09 Henderson Samuel T Methods for reducing levels of disease associated proteins
WO2007001883A2 (en) * 2005-06-20 2007-01-04 Accera, Inc. Method to reduce oxidative damage and improve mitochondrial efficiency
EP2001293B9 (en) * 2006-04-03 2019-04-17 Accera, Inc. Use of ketogenic compounds for treatment of age-associated memory impairment
EP2650381B1 (en) 2007-07-31 2016-09-21 Accera, Inc. Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function
US8105809B2 (en) * 2008-07-03 2012-01-31 Accera, Inc. Enzymatic synthesis of acetoacetate esters and derivatives
CN102105071A (zh) * 2008-07-03 2011-06-22 艾克塞拉公司 用于治疗神经性障碍的乙酰乙酸的单甘油酯及其衍生物
ITPI20090066A1 (it) * 2009-05-26 2010-11-27 Consiglio Nazionale Ricerche Metodo per produrre un dispositivo applicabile a tessuti biologici, in particolare un patch per trattare tessuti danneggiati, e dispositivo ottenuto con tale metodo
DE102009056745A1 (de) * 2009-12-04 2011-06-09 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System für die Verabreichung von Peptiden
US8828181B2 (en) 2010-04-30 2014-09-09 E I Du Pont De Nemours And Company Temperature switchable adhesives comprising a crystallizable oil
US8409703B2 (en) 2010-07-23 2013-04-02 E I Du Pont De Nemours And Company Temperature switchable adhesive assemblies with temperature non-switchable tack
DE102019201430A1 (de) 2019-02-05 2020-08-06 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System (TTS) mit Transportmedium
DE102019201431A1 (de) 2019-02-05 2020-08-06 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System (TTS) mit Feststoffreservoir
CN114269330A (zh) * 2019-06-28 2022-04-01 帕斯帕特技术有限公司 透皮药物递送贴片、药物递送系统和药物递送方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US921363A (en) 1908-07-09 1909-05-11 William L Chrysler Pitman connection.
US3996934A (en) * 1971-08-09 1976-12-14 Alza Corporation Medical bandage
JPS5620514A (en) * 1979-07-27 1981-02-26 Nitto Electric Ind Co Ltd Plaster for remedy of skin disease
JPS596285B2 (ja) * 1980-09-22 1984-02-10 日東電工株式会社 外用部材
JPS57116011A (en) * 1981-01-08 1982-07-19 Nitto Electric Ind Co Ltd Pharmaceutical preparation
JPS58148815A (ja) * 1982-02-26 1983-09-05 Nitto Electric Ind Co Ltd 複合医薬製剤の製法
DE3344691A1 (de) * 1983-12-10 1985-06-20 Bayer Ag, 5090 Leverkusen Wirkstoffabgasesysteme
EP0156080B2 (en) * 1984-03-05 1993-10-20 Nitto Denko Corporation Percutaneous absorption type adhesive pharmaceutical preparation
IL72684A (en) * 1984-08-14 1989-02-28 Israel State Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
US4765985A (en) * 1985-03-05 1988-08-23 Ciba-Geigy Corporation Devices and methods for treating memory impairment
US4680172A (en) * 1985-03-05 1987-07-14 Ciba-Geigy Corporation Devices and methods for treating memory impairment
US4668506A (en) * 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
DE3629304A1 (de) * 1986-08-28 1988-03-24 Lohmann Gmbh & Co Kg Transdermales therapeutisches system, seine verwendung und verfahren zu seiner herstellung
US4917676A (en) * 1986-11-20 1990-04-17 Ciba-Geigy Corporation User-activated transdermal therapeutic system
DE3743945A1 (de) * 1987-09-01 1989-03-09 Lohmann Gmbh & Co Kg Vorrichtung zur abgabe von stoffen, verfahren zu ihrer herstellung sowie ihre verwendung
DE3843239C1 (ko) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts

Also Published As

Publication number Publication date
IE64834B1 (en) 1995-09-06
LT3705B (en) 1996-02-26
IL92679A0 (en) 1990-09-17
CS719289A3 (en) 1992-06-17
NO895172D0 (no) 1989-12-21
DK651189D0 (da) 1989-12-20
PL160971B1 (en) 1993-05-31
LV10383A (lv) 1995-02-20
HU896714D0 (en) 1990-02-28
LTIP1589A (en) 1995-06-26
CA2006398C (en) 1997-04-15
CN1044226A (zh) 1990-08-01
JPH0315476A (ja) 1991-01-23
PH25852A (en) 1991-12-02
FI95774C (fi) 1996-03-25
LV10383B (en) 1995-10-20
ATE105489T1 (de) 1994-05-15
FI896098A0 (fi) 1989-12-19
NO180107C (no) 1997-02-26
KR950015057B1 (ko) 1995-12-21
JPH0784380B2 (ja) 1995-09-13
YU47076B (sh) 1994-12-28
DE3843238C1 (ko) 1990-02-22
HU206041B (en) 1992-08-28
AU613814B2 (en) 1991-08-08
DD290582A5 (de) 1991-06-06
YU240689A (en) 1991-04-30
PT92651A (pt) 1990-06-29
HUT54043A (en) 1991-01-28
EP0377147A2 (de) 1990-07-11
DK651189A (da) 1990-06-23
AU4684489A (en) 1990-06-28
NO180107B (no) 1996-11-11
IE894078L (en) 1990-06-22
NZ231908A (en) 1991-10-25
FI95774B (fi) 1995-12-15
CA2006398A1 (en) 1990-06-22
EP0377147A3 (en) 1990-12-27
ES2057080T3 (es) 1994-10-16
US5391375A (en) 1995-02-21
NO895172L (no) 1990-06-25
DE58907649D1 (de) 1994-06-16
RU2052997C1 (ru) 1996-01-27
PT92651B (pt) 1995-09-12
GEP19980993B (en) 1998-03-26
EP0377147B1 (de) 1994-05-11
MY105073A (en) 1994-07-30
ZA899882B (en) 1990-09-26
CS277067B6 (en) 1992-11-18

Similar Documents

Publication Publication Date Title
KR900009064A (ko) 활성 성분으로서 피소스티그민으로 구성된 경피 치료계 및 그것의 제조방법
KR900009065A (ko) 활성 성분으로 피소스티그민을 함유하는 경피 치료 시스템 및 그 제조방법
US5700480A (en) Transdermal therapeutic system comprising galanthamine as active component
KR910009249A (ko) 활성 성분으로 부프레노르핀(Buprenorphine)을 함유하는 경피 치료 시스템
US5415903A (en) Self-adhesive laminate for toe and fingernails
IL185686A (en) Subcutaneous medical system without fibers and method of manufacture
KR100674768B1 (ko) 데옥시페가닌 경피 치료 시스템
JP2002537244A5 (ja) デオキシペガニン含有の経皮治療用薬剤
CA2552679C (en) Tulobuterol adhesive patch
KR900009063A (ko) 노르 슈도에페드린 함유의 경피치료용 시스템
RU95113504A (ru) Трансдермальная терапевтическая система и способ ее получения
KR950703948A (ko) 피부를 통해 피소스티그민을 투여하기 위한 경피치료계, 및 이러한 계의 제조방법(transdermal therapeutic system for administering physostigmin through the skin〈 and a method of producing the system)
SI8912406B (sl) Postopek za izdelavo transdermalnega terapevtskega sistema s fizostigminom kot dejavno sestavino
DK175981B1 (da) Farmaceutisk præparat til transdermal systemisk administration af et farmakologisk aktivt middel, indeholdende tizanidin samt fremgangsmåde til fremstilling af præparatet
RU2001101440A (ru) Препарат, содержащий тринитрат глицерина, способ его получения и применение

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19991119

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee